Clinical Trial Update: Lanifibranor in Patients With Type 2 Diabetes & Nonalcoholic Fatty Liver Disease [Phase 2]

View source ↗

Summary

Phase 2 trial of lanifibranor in patients with nonalcoholic fatty liver disease and type 2 diabetes completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonalcoholic Fatty Liver Disease
• Type 2 Diabetes Mellitus

Drugs mentioned

• Lanifibranor (lanifibranor)

Snippet

Sponsor: University of Florida | Conditions: Nonalcoholic Fatty Liver Disease (NAFLD), Type 2 Diabetes (T2DM) | Phase 2 | Status: COMPLETED | Results posted: 2024-09-19